Characterization of the Exocrine Pancreas in the Male Zucker Diabetic Fatty Rat Model of Type 2 Diabetes Mellitus Following 3 Months of Treatment With Sitagliptin
| Autor: | Daniel J. Holder, Clay B. Frederick, Adam Smith, Caron L. Cunningham, Xiaorui Yao, Srinivasa Prahalada, Markus Dey, Thomas Forest |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Blood Glucose
Male medicine.medical_specialty endocrine system diseases Administration Oral Incretin Diabetes Mellitus Experimental Endocrinology Diabetes mellitus Internal medicine medicine Animals Hypoglycemic Agents Dosing Cell Proliferation business.industry Body Weight Sitagliptin Phosphate nutritional and metabolic diseases Type 2 Diabetes Mellitus Triazoles medicine.disease Glucagon-like peptide-1 Metformin Pancreas Exocrine Rats Rats Zucker Disease Models Animal Ki-67 Antigen medicine.anatomical_structure Diabetes Mellitus Type 2 Pyrazines Sitagliptin Keratins Pancreas business medicine.drug |
| Zdroj: | Endocrinology. 155:783-792 |
| ISSN: | 1945-7170 0013-7227 |
| Popis: | Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor-based incretin therapy intended for the treatment of type 2 diabetes mellitus (T2DM), has not been linked to adverse effects on the pancreas in prospective clinical trials or in nonclinical toxicology studies. To further assess potential pancreatic effects, sitagliptin was studied in the male Zucker diabetic fatty (ZDF) rat model of T2DM. Following 3 months of oral dosing with vehicle, or sitagliptin at doses 3- to 19-fold above the clinically therapeutic plasma concentration, which increased active plasma glucagon-like peptide-1 levels up to approximately 3-fold, or following 3 months of oral dosing with metformin, a non-incretin-based reference T2DM treatment, the pancreas of male ZDF rats was evaluated using qualitative and quantitative histopathology techniques. In the quantitative evaluation, proliferative index was calculated in exocrine pancreatic ducts and ductules using computer-based image analysis on sections stained by immunohistochemistry for cytokeratin (a cytoplasmic epithelial cell marker) and Ki-67 (a nuclear marker of recent cell division). Relative to controls, sitagliptin treatment did not alter disease progression based on detailed clinical signs and clinical pathology assessments. Sitagliptin treatment did not result in pancreatitis or any adverse effect on the pancreas based on a qualitative histopathology evaluation. Proliferative index did not increase with sitagliptin treatment based on quantitative assessment of more than 5000 sections of pancreas, where control group means ranged from 0.698-0.845% and sitagliptin-treated group means ranged from 0.679-0.701% (P = .874). Metformin treatment was similarly evaluated and found not to have adverse effects on pancreas. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|